Ketamine for anxiety: all studies (page 10)

Preoperative Anxiety's Impact on the Median Effective Dose of Esketamine for Alleviating Propofol Injection Pain in Patients Undergoing Painless abortion: A Randomized, Double-Blind, Controlled Trial.

Drug Design, Development and Therapy 2024 Yanping Shen, Lijun Yin, Binnan Hu et al. 7 citations

Propofol injection pain (PIP) is a frequent adverse effect during anesthesia induction, impacting patient comfort and satisfaction. Esketamine has been shown to alleviate PIP, but the optimal dose, especially in relation to preoperative anxiety levels, remains unclear. Preoperative anxiety may heighten pain perception and influence analgesic requirements. A randomized, double-blind, controlled...

DOI: 10.2147/DDDT.S482019 Full text Esketamine Dose-response Painless abortion Preoperative anxiety +6

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)

Psychiatry Research July 29, 2023 Mauro Pettorruso, Roberto Guidotti, Giacomo D’andrea et al. 56 citations

Treatment-resistant depression (TRD) represents a severe clinical condition with high social and economic costs. Esketamine Nasal Spray (ESK-NS) has recently been approved for TRD by EMA and FDA, but data about predictors of response are still lacking. Thus, a tool that can predict the individual patients' probability of response to ESK-NS is needed. This study investigates sociodemographic and...

DOI: 10.1016/j.psychres.2023.115378 Treatment-resistant depression Major depressive disorder Anxiety Rating scale +6

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group

American Journal of Geriatric Psychiatry July 8, 2023 Giacomo D’andrea, Stefania Chiappini, Roger S McIntyre et al. 36 citations

INTRODUCTION: Treatment-resistant depression (TRD) is a serious and debilitating psychiatric disorder that frequently affects older patients. Esketamine nasal spray (ESK-NS) has recently been approved as a treatment for TRD, with multiple studies establishing its efficacy and tolerability. However, the real-world effectiveness, tolerability, and safety of this treatment in older adults is still...

DOI: 10.1016/j.jagp.2023.06.016 Treatment-resistant depression Anxiety Major depressive disorder Tolerability +5

Efficacy of repeated intravenous esketamine in adolescents with anxious versus non-anxious depression.

General Psychiatry June 21, 2023 Xiaofeng Lan, Chengyu Wang, Fan Zhang et al.

Background: Patients with anxious major depressive disorder (MDD) are more likely to have poorer outcomes than those with non-anxious MDD. However, the effect of esketamine on adolescents with anxious versus non-anxious MDD has remained unknown. Aims: We compared the efficacy of esketamine in adolescents with MDD and suicidal ideation, both anxious and non-anxious. Methods: Fifty-four...

DOI: 10.1136/gpsych-2023-101007 Full text Anxiety Suicidal ideation Adolescent psychiatry Depressive disorder, major

Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity

The World Journal of Biological Psychiatry June 20, 2023 Maria Gałuszko‐węgielnik, Katarzyna Jakuszkowiak‐wojten, Alina Wilkowska et al. 9 citations

OBJECTIVES: Borderline personality disorder (BPD) and bipolar disorder (BD) often co-occur and frequently do not respond adequately to traditional antidepressant treatments. Ketamine has shown rapid antidepressant and anti-suicidal effects. However, there is limited literature on the safety and tolerance of using ketamine to treat patients with comorbid BD and BPD. METHODS: This case presents a...

DOI: 10.1080/15622975.2023.2227901 Ketamine Major depressive disorder Anxiety Borderline personality disorder +9

A single dose of ketamine enhances early life stress-induced aggression with no effect on fear memory, anxiety-like behavior, or depression-like behavior in mice

Behavioral Neuroscience June 15, 2023 Caitlyn J Bartsch, Sophia Aaflaq, Jessica T. Jacobs et al.

Ketamine is a dissociative anesthetic that has been shown to have antidepressant effects in humans and has been proposed as a potential treatment for mood disorders such as PTSD and aggression. However, previous studies from our lab and others have demonstrated that ketamine’s effects are highly context- and dose-dependent. In a recent study, we found that 10 mg/kg ketamine could exacerbate the...

DOI: 10.1037/bne0000560 Full text

Assessment of health-related quality of life and health status in patients with treatment-resistant depression treated with esketamine nasal spray plus an oral antidepressant

Health and Quality of Life Outcomes May 8, 2023 Carol Jamieson, Vanina Popova, Ella Daly et al. 18 citations

BACKGROUND: Patients with treatment-resistant depression (TRD) report significant deficits in physical and mental health, as well as severely impaired health-related quality of life (HRQoL) and functioning. Esketamine effectively enhances the daily functioning in these patients while also improving their depressive symptoms. This study assessed HRQoL and health status of patients with TRD, who...

DOI: 10.1186/s12955-023-02113-1 Treatment-resistant depression Anxiety Depression economics Nasal spray +6

Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study

European Neuropsychopharmacology May 4, 2023 Stefania Chiappini, Giacomo D’andrea, Sergio De Filippis et al. 48 citations

Esketamine, the S-enantiomer of ketamine, has recently emerged as a therapy for treatment-resistant depression (TRD), showing both rapid antidepressant action and good efficacy and high safety. It is also indicated for the acute short-term treatment of psychiatric emergency due to major depressive disorder (MDD) and for depressive symptoms in adults with MDD with acute suicidal...

DOI: 10.1016/j.euroneuro.2023.04.011 Major depressive disorder Treatment-resistant depression Anxiety Tolerability +8

The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis.

Journal of Affective Disorders May 1, 2023 Tuuli M. Hietamies, L. Mcinnes, A. Klise et al.

INTRODUCTION Ketamine intravenous therapy (KIT) appears effective for treating depression in controlled trials testing a short series of infusions. A rapidly proliferating number of clinics offer KIT for depression and anxiety, using protocols without a strong evidence basis. Controlled comparison of mood and anxiety from real-world KIT clinics, and the stability of outcomes, is lacking....

DOI: 10.1016/j.jad.2023.04.141 Full text

A Comparison of the Anti-Anxiety Effects of Oral Ketamine and Fluvoxamine in Children with Separation Anxiety Disorder Manifesting as School Refusal

Advanced Biomedical Research April 1, 2023 Afsaneh Karbasi Amel, Farzaneh Hosseini 5 citations

Background: Children suffer from a high prevalence of anxiety problems that require prompt treatment. It has been demonstrated that ketamine offers rapid anti-anxiety effects. This study aimed to evaluate ketamine's anti-anxiety impact in the treatment of children with school-refusal separation anxiety disorder. Materials and Methods: In this open-labeled randomized clinical trial, 71 children...

DOI: 10.4103/abr.abr_388_22